NCT06232564View on ClinicalTrials.gov

A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

March 2, 2028

Study Completion Date

August 2, 2028

Conditions
Neuroendocrine Tumors
Interventions
COMBINATION_PRODUCT

Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy

Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy

Trial Locations (1)

W12 0HS

RECRUITING

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
lead

Imperial College London

OTHER